DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
AMG-319
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Neoplasms; Carcinoma, Squamous Cell
PI3-kinase p110-delta subunit inhibitor
AMG-319
×
Maximum Phase:
2
First Approval:
None
UNII:
19DG7G1U5Q
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IDH305
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Neoplasms; Glioma
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH305
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C23H22F4N6O2
Molecular Weight:
490.46
AlogP:
5.12
PSA:
93.13
HBD:
1.0
HBA:
#RotB:
6.0
Source:
MG4101
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
MG4101
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BW250/183
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BW250/183
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DEPATUXIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Adenocarcinoma
Epidermal growth factor receptor erbB1 inhibitor
DEPATUXIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
W984C353CG
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOREFORANT TARTRATE
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Arthritis, Rheumatoid; Asthma; Psoriasis
Unknown
TOREFORANT TARTRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
HSV17TLD9C
Molecule Type:
Small molecule
Molecular Formula:
C50H70N12O6
Molecular Weight:
935.19
AlogP:
4.48
PSA:
69.73
HBD:
2.0
HBA:
#RotB:
6.0
Source:
OBICETRAPIB
2
Small molecule
Investigational
Unknown
Unknown
Lipid Metabolism Disorders
Cholesteryl ester transfer protein inhibitor
OBICETRAPIB
×
Maximum Phase:
2
First Approval:
None
UNII:
8O74K609HN
Molecule Type:
Small molecule
Molecular Formula:
C32H31F9N4O5
Molecular Weight:
722.61
AlogP:
8.67
PSA:
105.09
HBD:
1.0
HBA:
#RotB:
11.0
Source:
GPI-0100
2
Unknown
Investigational
Unknown
Unknown
Neoplasms; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Renal Cell
Unknown
GPI-0100
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VELNEPERIT
2
Small molecule
Investigational
Unknown
Unknown
Obesity
Neuropeptide Y receptor type 5 antagonist
VELNEPERIT
×
Maximum Phase:
2
First Approval:
None
UNII:
09BQ2KJ22J
Molecule Type:
Small molecule
Molecular Formula:
C17H24F3N3O3S
Molecular Weight:
407.46
AlogP:
3.32
PSA:
88.16
HBD:
2.0
HBA:
#RotB:
4.0
Source:
ISTAROXIME
2
Small molecule
Investigational
Unknown
Unknown
Heart Failure; Shock
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator
ISTAROXIME
×
Maximum Phase:
2
First Approval:
None
UNII:
W8I9H2TPPL
Molecule Type:
Small molecule
Molecular Formula:
C21H32N2O3
Molecular Weight:
360.5
AlogP:
3.11
PSA:
81.75
HBD:
1.0
HBA:
#RotB:
3.0
Source:
TRILACICLIB
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Hemangiosarcoma; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms
Cyclin-dependent kinase 4 inhibitor
TRILACICLIB
×
Maximum Phase:
2
First Approval:
None
UNII:
U6072DO9XG
Molecule Type:
Small molecule
Molecular Formula:
C24H30N8O
Molecular Weight:
446.56
AlogP:
2.72
PSA:
91.21
HBD:
2.0
HBA:
#RotB:
3.0
Source:
PF-05212377
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Serotonin 6 (5-HT6) receptor antagonist
PF-05212377
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OLTIPRAZ
2
Small molecule
Investigational
Unknown
Unknown
Lung Neoplasms; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease
Unknown
OLTIPRAZ
×
Maximum Phase:
2
First Approval:
None
UNII:
6N510JUL1Y
Molecule Type:
Small molecule
Molecular Formula:
C8H6N2S3
Molecular Weight:
226.35
AlogP:
3.3
PSA:
25.78
HBD:
0.0
HBA:
#RotB:
1.0
Source:
DU 125530
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder
Serotonin 1a (5-HT1a) receptor antagonist
DU 125530
×
Maximum Phase:
2
First Approval:
None
UNII:
ZB05V621UD
Molecule Type:
Small molecule
Molecular Formula:
C23H26ClN3O5S
Molecular Weight:
492.0
AlogP:
2.86
PSA:
79.39
HBD:
0.0
HBA:
#RotB:
6.0
Source:
PROPAGERMANIUM
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Glomerulosclerosis, Focal Segmental
Unknown
PROPAGERMANIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
1Q2P9TO9Q7
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CEP-11981
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Prostatic Neoplasms
Tyrosine-protein kinase TIE-2 inhibitor
CEP-11981
×
Maximum Phase:
2
First Approval:
None
UNII:
J8AY0Z4CBP
Molecule Type:
Small molecule
Molecular Formula:
C28H27N7O
Molecular Weight:
477.57
AlogP:
4.73
PSA:
89.66
HBD:
2.0
HBA:
#RotB:
4.0
Source:
ABT-751
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Neuroblastoma
Tubulin beta inhibitor
ABT-751
×
Maximum Phase:
2
First Approval:
None
UNII:
WDT5V5OB9F
Molecule Type:
Small molecule
Molecular Formula:
C18H17N3O4S
Molecular Weight:
371.42
AlogP:
3.34
PSA:
100.55
HBD:
3.0
HBA:
#RotB:
6.0
Source:
TRIDECANOATE
2
Small molecule
Investigational
Unknown
Unknown
Rett Syndrome
Unknown
TRIDECANOATE
×
Maximum Phase:
2
First Approval:
None
UNII:
19936LIY2V
Molecule Type:
Small molecule
Molecular Formula:
C13H26O2
Molecular Weight:
214.35
AlogP:
4.38
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
11.0
Source:
NOLPITANTIUM
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative
Unknown
NOLPITANTIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
NR72W2V70N
Molecule Type:
Small molecule
Molecular Formula:
C37H45Cl2N2O2+
Molecular Weight:
620.69
AlogP:
8.23
PSA:
29.54
HBD:
0.0
HBA:
#RotB:
9.0
Source:
POL6326
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
POL6326
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CINPANEMAB
2
Antibody
Investigational
Unknown
Unknown
Parkinson Disease
Alpha-synuclein inhibitor
CINPANEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
W83JGQ40XX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEGIPANERMIN
2
Protein
Investigational
Unknown
Unknown
Alzheimer Disease; Severe Acute Respiratory Syndrome
Unknown
PEGIPANERMIN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LERONLIMAB
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Graft vs Host Disease; HIV Infections; Neoplasms; Non-alcoholic Fatty Liver Disease; Severe Acute Respiratory Syndrome
C-C chemokine receptor type 5 antagonist
LERONLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
Y1J4NP8FF0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FOSDAGROCORAT
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Glucocorticoid receptor modulator
FOSDAGROCORAT
×
Maximum Phase:
2
First Approval:
None
UNII:
HPI19004QS
Molecule Type:
Small molecule
Molecular Formula:
C29H30F3N2O5P
Molecular Weight:
574.54
AlogP:
6.28
PSA:
108.75
HBD:
3.0
HBA:
#RotB:
6.0
Source:
NCX 1000
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Portal
Unknown
NCX 1000
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C38H55NO10
Molecular Weight:
685.86
AlogP:
6.55
PSA:
154.66
HBD:
2.0
HBA:
#RotB:
14.0
Source:
LADARIXIN
2
Small molecule
Investigational
Unknown
Unknown
Pemphigoid, Bullous; Diabetes Mellitus, Type 1
Interleukin-8 receptor A modulator
LADARIXIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DEH7Q6472O
Molecule Type:
Small molecule
Molecular Formula:
C11H12F3NO6S2
Molecular Weight:
375.35
AlogP:
1.09
PSA:
106.61
HBD:
1.0
HBA:
#RotB:
5.0
Source:
GSK239512
2
Small molecule
Investigational
Unknown
Unknown
Dementia; Multiple Sclerosis; Alzheimer Disease; Multiple Sclerosis, Relapsing-Remitting; Schizophrenia
Histamine H3 receptor antagonist
GSK239512
×
Maximum Phase:
2
First Approval:
None
UNII:
4I7U5C459M
Molecule Type:
Small molecule
Molecular Formula:
C23H27N3O2
Molecular Weight:
377.49
AlogP:
3.95
PSA:
45.67
HBD:
0.0
HBA:
#RotB:
4.0
Source:
IPL-344
2
Unknown
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis
Unknown
IPL-344
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AFN-1252
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Enoyl-[acyl-carrier-protein] reductase [NADH] inhibitor
AFN-1252
×
Maximum Phase:
2
First Approval:
None
UNII:
T3O718IKKM
Molecule Type:
Small molecule
Molecular Formula:
C22H21N3O3
Molecular Weight:
375.43
AlogP:
3.69
PSA:
75.44
HBD:
1.0
HBA:
#RotB:
4.0
Source:
TXA127
2
Protein
Investigational
Unknown
Unknown
Obesity; Peripheral Arterial Disease; HIV Infections; Hypertension; Myelodysplastic Syndromes; Neoplasms; Respiratory Insufficiency; Severe Acute Respiratory Syndrome
Proto-oncogene Mas agonist
TXA127
×
Maximum Phase:
2
First Approval:
None
UNII:
IJ3FUK8MOF
Molecule Type:
Protein
Molecular Formula:
C41H62N12O11
Molecular Weight:
899.02
AlogP:
-1.83
PSA:
377.24
HBD:
13.0
HBA:
#RotB:
25.0
Source:
SCYLLITOL
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Bipolar Disorder; Down Syndrome
Unknown
SCYLLITOL
×
Maximum Phase:
2
First Approval:
None
UNII:
1VS4X81277
Molecule Type:
Small molecule
Molecular Formula:
C6H12O6
Molecular Weight:
180.16
AlogP:
-3.83
PSA:
121.38
HBD:
6.0
HBA:
#RotB:
0.0
Source:
TENOFOVIR EXALIDEX
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Communicable Diseases
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
TENOFOVIR EXALIDEX
×
Maximum Phase:
2
First Approval:
None
UNII:
K7J545MEMA
Molecule Type:
Small molecule
Molecular Formula:
C28H52N5O5P
Molecular Weight:
569.73
AlogP:
6.86
PSA:
134.61
HBD:
2.0
HBA:
#RotB:
25.0
Source:
ARRY-502
2
Small molecule
Investigational
Unknown
Unknown
Asthma
G protein-coupled receptor 44 antagonist
ARRY-502
×
Maximum Phase:
2
First Approval:
None
UNII:
5LO1ZK1LCW
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
METHYLCOBALAMIN
2
Small molecule
Investigational
Unknown
Unknown
Multiple Sclerosis; Autistic Disorder
Unknown
METHYLCOBALAMIN
×
Maximum Phase:
2
First Approval:
None
UNII:
BR1SN1JS2W
Molecule Type:
Small molecule
Molecular Formula:
C63H91CoN13O14P
Molecular Weight:
1344.4
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
TOPIROXOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Hyperuricemia
Xanthine dehydrogenase inhibitor
TOPIROXOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
0J877412JV
Molecule Type:
Small molecule
Molecular Formula:
C13H8N6
Molecular Weight:
248.25
AlogP:
1.8
PSA:
91.14
HBD:
1.0
HBA:
#RotB:
2.0
Source:
1
2
…
131
132
133
134
135
136
137
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA